Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group
暂无分享,去创建一个
A. Look | A. Naranjo | J. Gastier-Foster | J. Maris | H. Shimada | W. London | M. Hogarty | R. Seeger | N. Ikegaki | S. Cohn | Julie R. Park | Patrick W. McGrady | Xao X. Tang | Larry Wang | R. Suganuma | Xao X. Tang
[1] A. Look,et al. Peripheral neuroblastic tumors with genotype–phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee , 2013, Pediatric blood & cancer.
[2] KyungMann Kim,et al. Contrasting treatment‐specific survival using double‐robust estimators , 2012 .
[3] W. Gerald,et al. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] J. Štěrba,et al. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma , 2011, Journal of Neuro-Oncology.
[5] Rainer König,et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas , 2008, Genome Biology.
[6] W. Hartmann,et al. Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91 , 2007, Clinical Cancer Research.
[7] C. Dang,et al. c-myc overexpression causes anaplasia in medulloblastoma. , 2006, Cancer research.
[8] M. Eilers,et al. Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.
[9] H. Shimada,et al. Large cell neuroblastoma , 2004, Cancer.
[10] Einar Hallberg,et al. Accumulation of c-Myc and proteasomes at the nucleoli of cells containing elevated c-Myc protein levels , 2003, Journal of Cell Science.
[11] Hiroyuki Shimada,et al. Morphologic features of neuroblastoma (Schwannian stroma‐poor tumors) in clinically favorable and unfavorable groups , 2002, Cancer.
[12] D. Stram,et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors , 2001, Cancer.
[13] L. Rorke,et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] P. Schürmann,et al. C‐MYC expression in medulloblastoma and its prognostic value , 2000, International journal of cancer.
[15] K K Matthay,et al. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .
[16] Hiroyuki Shimada,et al. Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.
[17] K K Matthay,et al. The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.
[18] Chi V. Dang,et al. c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.
[19] S. Joos,et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Stram,et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S. Perkins,et al. Expression of the c‐Myc Protein in Childhood Medulloblastoma , 1998, Journal of pediatric hematology/oncology.
[22] S. Cohn,et al. Advances in the diagnosis and treatment of neuroblastoma , 1998, Current opinion in oncology.
[23] B. Korf,et al. myc gene amplification and expression in primary human neuroblastoma. , 1990, Cancer research.
[24] M. Schwab,et al. Suppression of MYC by high expression of NMYC in human neuroblastoma cells , 1989, Journal of neuroscience research.
[25] W. Sadee,et al. Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line. , 1987, Cancer research.
[26] H. Sather,et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.
[27] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[28] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[29] W. Sieber,et al. Prognostic Factors in Neuroblastoma , 1971, Annals of surgery.
[30] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[31] H. Shimada,et al. Pathology of peripheral neuroblastic tumors: Significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma , 2008, Pathology & Oncology Research.
[32] D. Stram,et al. Enlarged and prominent nucleoli may be indicative of MYCN amplification , 2005, Cancer.
[33] J. Lunec,et al. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. , 2001, Medical and pediatric oncology.
[34] D. Stram,et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.